**Amendments to the Claims**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims**

1. (Currently Amended) An ophthalmic transdermal patch for treating diseases of the posterior segment of the eye comprising a drug-containing layer uniformly containing in a base matrix ~~10~~ 20 W/W% of polyoxyethylene oleyl ether and 10-20 W/W% of isopropyl myristate as percutaneous absorption enhancers and a drug to be delivered to at least a part of the posterior segment of the eye including the lens, the vitreous body, the choroid and the retina.

2. (Original) The ophthalmic transdermal patch of claim 1 wherein the drug is an anti-cataract agent, an anti-inflammatory agent, an anti-viral agent, an immunosuppressant, a calcium channel antagonist, a glutamate receptor antagonist or a cysteine protease inhibitor.

3-5. (Canceled)

6. (Previously presented) The ophthalmic transdermal patch of claim 1 wherein the base matrix comprises acrylic adhesive, silicone elastomer or styrene-isoprene-styrene copolymer.

7. (Canceled)

8. (Previously presented) The ophthalmic transdermal patch of claim 1 wherein the drug is a steroidal drug.

9. (Previously presented) The ophthalmic transdermal patch of claim 1 wherein the drug is a compound of the formula (1)



(1)

or a pharmaceutically acceptable salt thereof, wherein $R^1$ denotes C1 - C4 alkyl, or C6 - C10 aryl which may be substituted, $R^2$ and $R^3$ are the same or different from each other and denote hydrogen or C1 - C4 alkyl, or are combined to form a C3 - C7 ring, and $R^4$ denotes aryl, cycloalkyl, or a lower alkyl which may be substituted with an aromatic heterocyclic ring.

10. (Original) The ophthalmic transdermal patch of claim 9 wherein the drug is N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinal or a pharmaceutically acceptable salt thereof.

11. (Currently Amended) A method for treating a disease of at least a part of the posterior segment of the eye including the lens, the vitreous body, the choroid and the retina in an animal including a human, wherein the method comprises applying to the animal a transdermal patch comprising a drug-containing layer uniformly containing in a base matrix an effective amount of a drug to be delivered to the part and 10~~-20~~ W/W% of polyoxyethylene oleyl ether and 10-20 W/W% of isopropyl myristate as percutaneous absorption enhancers.

12. (Original) The method of claim 11 wherein the drug is an anti-cataract agent, an anti-inflammatory agent, an anti-viral agent, an immunosuppressant, a calcium channel antagonist, a glutamate receptor antagonist or a cysteine protease inhibitor.

13-15. (Canceled)

16. (Original) The method of claim 11 wherein the base matrix comprises acrylic adhesive, silicone elastomer or styrene-isoprene-styrene copolymer.

17. (Canceled)

18. (Original) The method of claim 11 wherein the drug is a steroidal drug.

19. (Original) The method of claim 11 wherein the drug is a compound of the formula (1)



(1)

or a pharmaceutically acceptable salt thereof, wherein $R^1$ denotes C1 - C4 alkyl, or C6 - C10 aryl which may be substituted, $R^2$ and $R^3$ are the same or different from each other and denote hydrogen or C1 - C4 alkyl, or are combined to form a C3 - C7 ring, and $R^4$ denotes aryl, cycloalkyl, or a lower alkyl which may be substituted with an aromatic heterocyclic ring.

20. (Previously Presented) The method of claim 19 wherein the drug is N-(4-fluorophenyl-sulfonyl)-L-valyl-L-leucinal or a pharmaceutically acceptable salt thereof.

21. (Currently Amended) An ophthalmic transdermal patch for treating diseases of the posterior segment of the eye comprising a drug-containing layer uniformly containing in a base matrix ~~10~~ 20 W/W% of polyoxyethylene oleyl ether and 10-20 W/W% of isopropyl myristate as percutaneous absorption enhancers and a drug to be delivered to at least a part of the posterior segment of the eye including the lens, the vitreous body, the choroid and the retina, wherein the drug is a steroidal drug or a compound of the formula (1)



(1)

or a pharmaceutically acceptable salt thereof, wherein $R^1$ denotes C1 - C4 alkyl, or C6 - C10 aryl which may be substituted, $R^2$ and $R^3$ are the same or different from each other and denote hydrogen or C1 - C4 alkyl, or are combined to form a C3 - C7 ring, and $R^4$ denotes aryl, cycloalkyl, or a lower alkyl which may be substituted with an aromatic heterocyclic ring.

22-24. (Canceled)

25. (Previously Presented) The ophthalmic transdermal patch of claim 21 wherein the base matrix comprises acrylic adhesive, silicone elastomer or styrene-isoprene-styrene copolymer.

26. (Canceled)

27. (Previously Presented) The ophthalmic transdermal patch of claim 21 wherein the drug is N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinal or a pharmaceutically acceptable salt thereof.

28. (Previously Presented) The ophthalmic transdermal patch of claim 21 wherein the steroidal drug is prednisolone.